Johnson & Johnson Innovation and the Biomedical Advanced Research and Development Authority (BARDA) have announced the ‘Blue Knight Resident QuickFire Challenge: Accel
Janssen’s chief scientific officer and worldwide chairman Paul Stoffels has said he hopes the company’s coronavirus vaccine candidate will be available by “early next year” to millions of people
GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial.<